IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: 10/628,554

Applicant

: David E. COMINGS et al.

Filed

: July 29, 2003

TC/A.U.

: 1614

Examiner

: To Be Assigned

Docket No. Customer No.

: 1954-390 : 06449

Confirmation No. : 3705

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office

P.O. Box 1450

Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§§1.56, 1.97 and 1.98, Applicant submits herewith copies of publications that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449. Respectfully submitted,

Respectfully sphmitted,

Michael G. Mullivan

Attorney for Applicants Registration No. 35,377

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

Enclosures: PTO-1449 Forms References

1954-390.ids.wpd

,			Complete if Known										
			Application Number	10/628,554									
INFO	RMAT	ON DISCLOSURE	Filing Date	July 29, 2003									
STAT	EMEN	T BY APPLICANT	First Named Inventor	David E. COMINGS et al.									
(JAN	6 2004 발	Group Art Unit	1614									
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	TA.	**************************************	Examiner Name	To Be Assigned									
Sheet	EN.	ADEMAN of 2	Attorney Docket Number	1954-390									
NON PATENT LITERATURE DOCUMENTS													
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published											
	1.	Barcellos, Lisa F., et al., "CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis," lmmunogenetics 51:281-288, 2000.											
	2. Bennetts, Bruce H., et al., "The CCR5 Deletion Mutation Fails to Protect Against Multi Schlerosis," <u>Human Immunology</u> 58:52-59, 1997.												
	3.	Biti, Robyn, et al., "HIV-1 infection in an individual homozygous for the <i>CCR5</i> deletion allele," Nature Medicine 3(3):252-253, March 1997.											
	4.	Challoner, Peter B., et al., "Plaque-associated expression of human herpesvirus 6 in multiple sclerosis," Proc. Natl. Acad. Sci. USA 92:7440-7444, August 1995.											
	5.	Cone, L., et al. "CC-CKR5 (CKR5) Delta 32 mutations alters the clinical course and immune status of HIV-1 infection," 13th Int. AIDS Conference, Durban, South Africa, TuPeA, p. 320, July 8-13, 2000.											
	6.	Dean, Michael, et al., "Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene," Science 273:1856-62, September 27, 1996.											
	7.	Ebers, George C., et al., "The role of genetic factors in multiple sclerosis susceptibility," Journal of Neuroimmunology 54:1-17, 1994.											
	8.	Koch-Henriksen, Nils, et al., "Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry," J. Neurol. Neurosurg. Psychiatry 65:56-59, 1998.											
	9.	Knox, Konstance K., et al., "Human Herpesvirus 6 and Multiple Sclerosis: Systemic Active Infections in Patients with Early Disease," Clinical Infectious Diseases 31:894-903, 2000.											
	10.	Lucotte, Gérard, et al., "Distribution of the <i>CCR</i> 5 Gene 32-bp Deletion in Europe," <u>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</u> 19:174-177, 1998.											
	11.	Martinson, Jeremy J., et al., "Global distribution of the <i>CCR5</i> gene 32-basepair4 deletion," Nature Genetics 16:100-103, May 16, 1997.											
	12.	Midgard, R., et al., "Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway," <u>Journal of Neurology, Neurosurgery, and Psychiatry</u> 58:417-421, 1995.											
Examiner Signature				Date Considered									

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

and the second of the second

ب	F. 15-4			Complete if Known						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number	10/628,554				
					Filing Date	July 29, 200	July 29, 2003			
				ANI	First Named Inventor	David E. COMINGS et al.				
					Group Art Unit	1614				
					Examiner Name	To Be Assigned				
Sheet RADEMAN of 2					Attorney Docket Number	1954-390				
				NON PA	TENT LITERATURE DOCU	MENTS				
Examiner Initials*	Cite No.1				hor (in CAPITAL LETTERS), title of the article (when appropriate), title of the irnal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²		
	13.	O'Brien, Thomas, et al., "HIV-1 Infection in a man homozygous of CCR5 _△ 32," <u>The Lancet</u> 349:1219-20, 1997.								
	14.	Oksenberg, Jorge R., et al., "Genetics of Demyelinating Diseases," <u>Brain Pathology</u> 6:289-302, 1996.								
	15.	Paxton, William A., et al., "RANTES Production from CD4+ Lymphocytes Correlates with Host Genotype and Rates of Human Immunodeficiency Virus Type 1 Disease Progession," The Journal of Infectious Diseases 183:1678-81, 2001.								
	16.	Poser, Charles M., et al., "The Dissemination of Multiple Sclerosis: A Viking Saga? A History Essay," Ann Neurol 36(S2):S231-S243, 1994.								
	17.	Sanders, Virginia J., et al., "Detection of Herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction," <u>Journal of NeuroVirology</u> 2:249-258, 1996.								
-	18.	Sawcer, Stephen, et al., "A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22," Nature Genetics 13:464-8, August 13, 1996.								
	19.	Sellebjerg, Finn, et al., "CCR5 Δ 32, matrix metalloproteinase-9 and disease activity in multiple sclerosis," <u>Journal of Neuroimmunology</u> 102:98-106, 2000.								
	20.	Simpson, Julie, et al., "Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue," <u>Journal of Neuroimmunology</u> 108:192-200, 2000.								
	21.	Sørensen, Torben L., et al., "Expression of specific chemokines and chemokine receptors the central nervous system of multiple sclerosis patients," <u>The Journal of Clinical Investigation</u> 103(6):807-15, 1999.								
	22.		or-α- Sec		reased Numbers of CCR5+ Interferon-γ- and Tumor Necrosis aphocytes in Multiple Sclerosis Patients," <u>Ann. Neurol.</u> 47:269-273,					
	23.	Zhang, G.X., et al., "Chemokines and Chemokine Receptors in the Pathogenesis of Multiple Sclerosis," Multiple Sclerosis 6:3-13, 2000.								
Examiner Signature					cornet citation is in conformation	Date Considered				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.